223 DAYS. 0 ATTACKS.* THE RIGHT THERAPY MATTERS

HAEGARDA is the HAE therapy that reduced attacks by 95%

* In a post-hoc analysis of 63 patients, median time to first attack in patients followed over 1.5 years in a long-term, open-label study was 224 days.1

In the pivotal trial, median reduction in the number of attacks in people receiving HAEGARDA 60 IU/kg vs placebo.

HAEGARDA is the only HAE preventive therapy that delivers:

arrow pointing downwards with 95 percent symbol

95% reduction in HAE attacks

arrow pointing downwards with 99 percent symbol

>99% less rescue medication use

icon of C1-INH

Replacing missing or dysfunctional C1-INH

MORE ABOUT EFFICACY

WAO Guideline for the Management of HAE states that patients should have HAE rescue medication available at all times.3

Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

§Median reduction in rescue medication use with HAEGARDA 60 IU/kg vs placebo.

Indication icon 6 years of age or older
Prescribing HAEGARDA

Get your patients started on HAEGARDA

PRESCRIBING HAEGARDA
REFERENCES: 1. Craig T, Feuersenger H, Pragst I. Durability of symptom control with long-term prophylactic therapy with subcutaneous C1-inhibitor in patients with hereditary angioedema. Presented at the 33rd Annual Eastern Allergy Conference. Palm Beach, FL. August 16-18, 2020. 2. Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140. 3. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EEACI guideline for the management of hereditary angioedema—the 2017 revision and update. Allergy. 2018;73(8):1575-1596.
;
You are now leaving the current website.

Do you want to continue?